(Q34148661)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

review article

1 reference

title

The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

0 references

0 references

systemic lupus erythematosus

0 references

author

René de Waal Malefyt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

Amy M Beebe

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Daniel J Cua

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 August 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

Cytokine and Growth Factor Reviews

12 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

403-412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

4-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysacchari

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Differential effects of IL-4 and IL-10 on IL-2-induced IFN-γ synthesis and lymphokine-activated killer activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10: a novel stimulatory factor for mast cells and their progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Human B cell precursors proliferate and express CD23 after CD40 ligation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Type 1 T regulatory cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 and the interleukin-10 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10 protects mice from lethal endotoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10 prevents necrosis in murine experimental acute pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10-deficient mice develop chronic enterocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Inhibition of cell-mediated immunity by IL4 and IL10.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Autoimmune disease in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IL-10 stimulates production of platelet-activating factor by monocytes of patients with active systemic lupus erythematosus (SLE)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 response abnormalities in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Impaired production of IL-12 in system lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Inactive systemic lupus erythematosus id associated with a normal stimulated Th(1)/Th(2) cytokine secretory pattern

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8(-) and CD8(+) T cells in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus. Weak correlations of cytokine production wi

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Detection of circulating FcɛR2/CD23+ monocytes in patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Comparison of platelet immunity in patients with SLE and with ITP.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

An investigation of polymorphism in the interleukin-10 gene promoter.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin 10 secretion in relation to human IL-10 locus haplotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Single nucleotide polymorphic haplotypes of the interleukin-10 5' flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Apoptosis in different cutaneous manifestations of lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Cytokine regulation of apoptosis and Bcl-2 expression in lymphocytes of patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Reduction of bcl-2 in T cells during immunosuppressive therapy in patients with severe juvenile onset systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Differential oncogene and TNF-alpha mRNA expression in bone marrow cells from systemic lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

T cell necessity in the pathogenesis of experimental autoimmune encephalomyelitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4,

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interferon-? therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Interleukin-10 prevents experimental allergic encephalomyelitis in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IL-10 fails to abrogate experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Modulating phenotype and cytokine production of leucocytic retinal infiltrate in experimental autoimmune uveoretinitis following intranasal tolerance induction with retinal antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IL-10 has a protective role in experimental autoimmune uveoretinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Abnormal functional behavior of peripheral blood mononuclear cells from Hashimoto's disease patients. Immunomodulatory effects of cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

IL-10 suppresses experimental autoimmune neuritis and down-regulates TH1-type immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Experimental autoimmune myocarditis and its pathomechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Immune modulation in pemphigus vulgaris: role of CD28 and IL-10

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2802%2900025-4

7 January 2021

10.1016/S1359-6101(02)00025-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12220553%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference